Patents by Inventor Paul Acton
Paul Acton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160158070Abstract: A method for in vitro testing of an absorbent article includes the steps of inserting the absorbent article into a radiolucent simulated body cavity, placing the radiolucent simulated body cavity into a radiolucent pressure chamber, placing the radiolucent pressure chamber into a radiological device, pressurizing the radiolucent pressure chamber to a predetermined pressure, providing test liquid through the test liquid port and to the absorbent article, acquiring data relating to the absorbent article and the test liquid via the radiological device and an associated computing device, and analyzing the acquired data. The radiological pressure chamber includes a simulated body cavity arranged and configured to accommodate the absorbent article, a test liquid port, and a pressure control system. The radiolucent test device has at least one radio scanning element rotatable about radiolucent test device support having the pressure chamber disposed thereon.Type: ApplicationFiled: December 9, 2014Publication date: June 9, 2016Inventors: Paul Acton, Mari Hou
-
Patent number: 8889138Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: October 11, 2010Date of Patent: November 18, 2014Assignees: Merck Sharp & Dohme Corp., Northwestern UniversityInventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Patent number: 8383113Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: February 8, 2012Date of Patent: February 26, 2013Assignees: Northwestern University, Merck Sharp & Dohme Corp.Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
-
Publication number: 20120171224Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: February 8, 2012Publication date: July 5, 2012Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
-
Patent number: 8128930Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: July 1, 2010Date of Patent: March 6, 2012Assignees: Northwestern University, Merck Sharp & Dohme Corp.Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William L. Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
-
Patent number: 8019807Abstract: A system for brokering business service requests in a computer network is disclosed. The system is operative to receive a request for information from a requester, transmit the request to a provider, and return a response to the requester. The broker typically comprises the following components. A requester-side processing stage operative to communicate with the requester; a provider-side processing stage operative to communicate with the provider; and a broking stage operative to exchange data between the requester-side processing stage and the provider-side processing stage. In operation of the business service broker, upon receipt of a request for a requester, the broking stage obtains data required to respond to the request by communicating with a provider through the provider-side processing stage. The brokering stage formulates a response and returns it to the requester through the requester-side processing stage. The mechanism by which the response is obtained is abstracted from the requester.Type: GrantFiled: April 11, 2002Date of Patent: September 13, 2011Assignee: Wireless Enterprise Solutions Technology LimitedInventors: Brian Connell, Paul Acton
-
Publication number: 20110159013Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: October 11, 2010Publication date: June 30, 2011Applicant: Merck & Co., Inc.Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L. Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Publication number: 20100272714Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: July 1, 2010Publication date: October 28, 2010Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kristen Viola
-
Patent number: 7811563Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: GrantFiled: October 21, 2005Date of Patent: October 12, 2010Assignees: Northwestern University, Merck & Co., Inc.Inventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Patent number: 7780963Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ?1-42.Type: GrantFiled: October 21, 2005Date of Patent: August 24, 2010Assignees: Merck & Co., Inc., Northwestern UniversityInventors: Paul Acton, Zhiqiang An, Andrew J. Bett, Robert Breese, Lei Chang, Elizabeth Chen Dodson, Gene Kinney, William Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola
-
Publication number: 20080175835Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLs, and tauphosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ? 1-42.Type: ApplicationFiled: October 21, 2005Publication date: July 24, 2008Applicants: Merck & Co., Inc., Northwestern UniversityInventors: Paul Acton, Zhigiang An, Andrew J. Bett, Robert Breese, Elizabeth Chen Dodson, Gene Kinney, William L. Klein, Mary P. Lambert, Xiaoping Liang, Paul Shughrue, William R. Strohl, Kirsten Viola, Lei Chang
-
Publication number: 20060228349Abstract: The present invention relates to antibodies that differentially recognize multi-dimensional conformations of A?-derived diffusible ligands, also known as ADDLs. The antibodies of the invention can distinguish between Alzheimer's Disease and control human brain extracts and are useful in methods of detecting ADDLs and diagnosing Alzheimer's Disease. The present antibodies also block binding of ADDLs to neurons, assembly of ADDLS, and tau phosphorylation and are there useful in methods for the preventing and treating diseases associated with soluble oligomers of amyloid ?1-42.Type: ApplicationFiled: October 21, 2005Publication date: October 12, 2006Inventors: Paul Acton, Zhiqiang An, Andrew Bett, Robert Breese, Lei Chang, Elizabeth Dodson, Gene Kinney, William Klein, Mary Lambert, Xiaoping Liang, Paul Shughrue, William Strohl, Kirsten Viola
-
Publication number: 20030074401Abstract: A system for brokering business service requests in a computer network is disclosed. The system is operative to receive a request for information from a requester, transmit the request to a provider, and return a response to the requester. The broker typically comprises the following components. A requester-side processing stage operative to communicate with the requester; a provider-side processing stage operative to communicate with the provider; and a broking stage operative to exchange data between the requester-side processing stage and the provider-side processing stage. In operation of the business service broker, upon receipt of a request for a requester, the broking stage obtains data required to respond to the request by communicating with a provider through the provider-side processing stage. The brokering stage formulates a response and returns it to the requester through the requester-side processing stage. The mechanism by which the response is obtained is abstracted from the requester.Type: ApplicationFiled: April 11, 2002Publication date: April 17, 2003Inventors: Brian Connell, Paul Acton